NovaBridge Biosciences (NBP) Current Deferred Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has reported Current Deferred Revenue for 6 consecutive years, with $305552.3 the latest figure, recorded in Q4 2023.

• Quarterly Current Deferred Revenue fell 74.96% year-over-year to $305552.3 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $305552.3 (down 74.96% YoY) and the FY2023 annual result came in at $600000.0, down 99.95% from the prior year.
• Current Deferred Revenue declined to $305552.3 in Q4 2023 per NBP's latest filing, from $1.5 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for NBP reached as high as $8.2 million in Q2 2022 and fell as low as $305552.3 in Q4 2023.
• A 5-year average of $1.7 million and a median of $1.1 million in 2020 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue jumped 1061.47% — and 2023, when it plunged 82.24%.
• Year by year, Current Deferred Revenue stood at $556172.6 in 2019, then surged by 103.72% to $1.1 million in 2020, then plunged by 37.69% to $706000.0 in 2021, then surged by 72.81% to $1.2 million in 2022, then tumbled by 74.96% to $305552.3 in 2023.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $305552.3, $1.5 million, and $1.2 million for Q4 2023, Q2 2023, and Q4 2022 respectively.